Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades

21 May 2019

Abstract excerpt

Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC) and other tumors; however, its association with TMB and survival in patients with immunotherapy remains unknown. Methods: We curated somatic mutation data and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31164891
DOI: 10.3389/fimmu.2019.01113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point BlockadesPMID 31164891Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.Semantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.Semantic proximity Read ↗

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read ↗

Mutated Processes Predict Immune Checkpoint Inhibitor Therapy Benefit in Metastatic MelanomaSemantic proximity Read ↗

LRP1B in cancer: From a mutation landscape to predictive biomarkers for precision oncology.Semantic proximity Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanomaSemantic proximity Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Semantic proximity Read ↗

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.